These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34635007)

  • 1. AZD3759 inhibits glioma through the blockade of the epidermal growth factor receptor and Janus kinase pathways.
    Yin W; Zhang K; Deng Q; Yu Q; Mao Y; Zhao R; Ma S
    Bioengineered; 2021 Dec; 12(1):8679-8689. PubMed ID: 34635007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1.
    Zhao R; Yin W; Yu Q; Mao Y; Deng Q; Zhang K; Ma S
    Bioengineered; 2022 Jan; 13(1):331-344. PubMed ID: 34738874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.
    Li X; Wang Y; Wang J; Zhang T; Zheng L; Yang Z; Xing L; Yu J
    Int J Cancer; 2018 Jul; 143(1):212-224. PubMed ID: 29430654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR inhibitor enhances cisplatin sensitivity of human glioma cells.
    Zhang Y; Xing X; Zhan H; Li Q; Fan Y; Zhan L; Yu Q; Chen J
    J Huazhong Univ Sci Technolog Med Sci; 2011 Dec; 31(6):773-778. PubMed ID: 22173497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation.
    Tavassoly O; Del Cid Pellitero E; Larroquette F; Cai E; Thomas RA; Soubannier V; Luo W; Durcan TM; Fon EA
    Neurotherapeutics; 2021 Apr; 18(2):979-997. PubMed ID: 33713002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
    Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
    Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity.
    Steinbach JP; Supra P; Huang HJ; Cavenee WK; Weller M
    Brain Pathol; 2002 Jan; 12(1):12-20. PubMed ID: 11770895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
    Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X; Bai Y; Rabbie S; Kim DW; Ahn MJ; Yang JC; Zhang X
    Sci Transl Med; 2016 Dec; 8(368):368ra172. PubMed ID: 27928026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of microRNA-133a and downregulation of connective tissue growth factor suppress cell proliferation, migration, and invasion in human glioma through the JAK/STAT signaling pathway.
    Zhang P; Chen FZ; Jia QB; Hu DF
    IUBMB Life; 2019 Dec; 71(12):1857-1875. PubMed ID: 31381269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High epiregulin expression in human U87 glioma cells relies on IRE1α and promotes autocrine growth through EGF receptor.
    Auf G; Jabouille A; Delugin M; Guérit S; Pineau R; North S; Platonova N; Maitre M; Favereaux A; Vajkoczy P; Seno M; Bikfalvi A; Minchenko D; Minchenko O; Moenner M
    BMC Cancer; 2013 Dec; 13():597. PubMed ID: 24330607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
    Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.
    Longo SL; Padalino DJ; McGillis S; Petersen K; Schirok H; Politz O; Canute GW; Post DE
    Invest New Drugs; 2012 Dec; 30(6):2161-72. PubMed ID: 22203214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models.
    Martin EC; Aarons L; Yates JWT
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):669-675. PubMed ID: 30054711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.
    Fan QW; Specht KM; Zhang C; Goldenberg DD; Shokat KM; Weiss WA
    Cancer Res; 2003 Dec; 63(24):8930-8. PubMed ID: 14695210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.
    Premkumar DR; Jane EP; Pollack IF
    Cancer Biol Ther; 2015; 16(2):233-43. PubMed ID: 25482928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling.
    Oh H; Hwang I; Jang JY; Wu L; Cao D; Yao J; Ying H; Li JY; Yao Y; Hu B; Wang Q; Zheng H; Paik J
    Cancer Res; 2021 Mar; 81(6):1528-1539. PubMed ID: 33509942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CBX3 promotes glioma U87 cell proliferation and predicts an unfavorable prognosis.
    Zhao SP; Wang F; Yang M; Wang XY; Jin CL; Ji QK; Li S; Zhao XL
    J Neurooncol; 2019 Oct; 145(1):35-48. PubMed ID: 31502042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
    Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
    Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.